Filing Details

Accession Number:
0000899243-19-028937
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-11 17:01:12
Reporting Period:
2019-12-09
Accepted Time:
2019-12-11 17:01:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1740547 Urovant Sciences Ltd. UROV () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1314596 Keith Katkin C/O Urovant Sciences, Inc.
5281 California Avenue, Suite 100
Irvine CA 92617
Peo;Ceo/Urovant Sciences, Inc. Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2019-12-09 120,000 $3.86 120,000 No 4 M Direct
Common Shares Disposition 2019-12-09 120,000 $12.78 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2019-12-09 120,000 $0.00 120,000 $3.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
881,254 2027-09-21 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.35 to $12.885. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed to minimize the potential impact of 280G excise tax, which may be triggered by the change of control resulting from the acquisition by Sumitomo Dainippon Pharma Co., Ltd. of Roivant Sciences Ltd.'s ownership interest in the Issuer. Following the reported transaction, the Reporting Person beneficially owns options to purchase an aggregate of 1,596,166 common shares.
  3. 25% of the total shares underlying the option vested and became exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.